Science & Technology

European Life Sciences Venture Fund Raises 472 Million Euros «Science and Enterprises

By Alan, October 19, 2021

(Gerd Altmann, pixabay. Https: //

October 19, 2021. Venture capital firms have raised € 472 million (US $ 548 million) to invest in life sciences and medical device start-ups in Europe. Sofinnova Partner With the new Capital X fund in Paris, the company says it has raised more than € 1 billion in the last 12 months.

Sofinnova Partners Early stage enterprise With disruptive technology for that investment. The company is identifying new companies developing biopharmacy, medical devices, or industrial biotechnology solutions for sustainability issues. According to Sofinnova Partners, funding goals are often technologies spun off from academic labs or assets spun off after being developed in corporate labs.

According to the company, it is investing in startups at various stages, from seed to late rounds. In addition, Sofinnova Partners said it will lead the establishment of the new company and will play a major role in financing the first venture round of the new company, known as Series A. Most of the investment is made in Europe, but Sofinnova Partners are companies in other parts of the world.

Investors from Europe, Asia and North America

Capital X is Sofinniva Partners’ tenth fund in the family, and is sourced from pension funds, insurers, foundations, endowments, corporate investors and prominent family offices, the company said. .. , And North America. Sofinniva Partners says it has raised over € 1 billion for various investment funds in the last 12 months. The latest one is Medtech Acceleration Fund We will support medical device startups in July.

Henricht Richter, Sofinnova Partners Managing Partners Company statementCapital X, € 472 million, is “the largest fund dedicated to early-stage healthcare investment in Europe”. Richter adds: “This is an important milestone for Sofinnova Partners. Capital X will enable us to leverage more than 30 years of accumulated experience in completing this strategy.” Sofinnova Partners has 25 total assets under its control. It says it will exceed 100 million euros.

Science & Enterprise reported on several Sofinnova Partners investments since 2012. The latest Sofinnova Partners story is about participating in an investment of € 60 million (US $ 73 million). Muna Therapeutics A start-up company discovering a cure for neurodegenerative diseases in Copenhagen, Denmark, in July 2021.

Other Science & Enterprise Articles:

* * *

European Life Sciences Venture Fund Raises 472 Million Euros «Science and Enterprises European Life Sciences Venture Fund Raises 472 Million Euros «Science and Enterprises

Back to top button